What's Hot
View all perspectives
Flu and Tofacitinib: Dr. Kathryn Dao
Dr. Kathryn Dao reviews abstract L04 at the 2020 ACR annual meeting.
Outcomes of COVID in Rheumatic Disease Patients: Dr. Eric Dein
Dr. Eric Dein reviews abstract L01 presented at the 2020 ACR annual meeting.
Robert B Chao, MD doctorRBC
4 years 5 months ago
Hey Google, does this patient have sacroilitis?
Artificial intelligence model validated for detection of radiographic sacroilitis.
@RheumNow #ACR20 Abs#2018 https://t.co/TDhGKC8ss4
Dr. Antoni Chan synovialjoints
4 years 5 months ago
What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884
Eric Dein ejdein1
4 years 5 months ago
Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow
Eric Dein ejdein1
4 years 5 months ago
Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Dr. Antoni Chan synovialjoints
4 years 5 months ago
The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890
Dr. John Cush RheumNow
4 years 5 months ago
Test your ACR IQ and see where you place on our leaderboard. #ACR20
https://t.co/DKSq8gKTDb https://t.co/lGUEbVbg1g
Pregnancy and ILD: Dr. David Liew
Dr. David Liew reviews abstract #1446 presented at the 2020 ACR annual meeting.
Eric Dein ejdein1
4 years 5 months ago
2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm
Robert B Chao, MD doctorRBC
4 years 5 months ago
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs.
⬇️radiographic spinal progression over 2 yrs
⬇️mSASSS progression
@RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
Mrinalini Dey DrMiniDey
4 years 5 months ago
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor
-HZ events more common in patients taking 30mg vs 15mg
-HZ more common in UPA vs those taking ADA+MTX & MTX
Abs#2002 #ACR20 @RheumNow
https://t.co/tQ03wBueW5
Bella Mehta bella_mehta
4 years 5 months ago
We as young physicians should start paying attention to our contracts-🤦♀️
1-know your worth (see MGMA compensation yearly)
2-malpractive/ tail coverage
3-non-compete
4-termination clause
5-guarantee/ RVU
@RheumNow
#ACR20 #5M036
David Liew drdavidliew
4 years 5 months ago
Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
Enormous potential, worth exploring!
Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs
Dr. John Cush RheumNow
4 years 5 months ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow and its Faculty.
Poster Hall